Insulet Corporation
$ 149.70
0.34%
12 Jun - close price
- Market Cap 10,368,922,000 USD
- Current Price $ 149.70
- High / Low $ 150.60 / 145.14
- Stock P/E 34.98
- Book Value 18.81
- EPS 4.28
- Next Earning Report 2026-08-06
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.10 %
- ROE 0.23 %
- 52 Week High 354.88
- 52 Week Low 140.63
About
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company is headquartered in Acton, Massachusetts.
Analyst Target Price
$242.43
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-06 | 2026-02-18 | 2025-11-06 | 2025-08-07 | 2025-05-08 | 2025-02-20 | 2024-11-07 | 2024-08-08 | 2024-05-09 | 2024-02-22 | 2023-11-02 | 2023-08-08 |
| Reported EPS | 1.3 | 1.55 | 1.24 | 1.17 | 1.02 | 1.15 | 0.9 | 0.55 | 0.73 | 1.4 | 0.71 | 0.38 |
| Estimated EPS | 1.16 | 1.46 | 1.15 | 0.92 | 0.79 | 1.021 | 0.76 | 0.56 | 0.4 | 0.66 | 0.41 | 0.26 |
| Surprise | 0.14 | 0.09 | 0.09 | 0.25 | 0.23 | 0.129 | 0.14 | -0.01 | 0.33 | 0.74 | 0.3 | 0.12 |
| Surprise Percentage | 12.069% | 6.1644% | 7.8261% | 27.1739% | 29.1139% | 12.6347% | 18.4211% | -1.7857% | 82.5% | 112.1212% | 73.1707% | 46.1538% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-06 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | 1.37 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: PODD
2026-06-12 20:07:28
DexCom Inc. shares experienced a strong trading day, rising 1.76% to $120.90, which allowed it to outperform its competitors, including Medtronic PLC and Abbott Laboratories, on the stock market. The stock closed $58.19 below its 52-week high, indicating potential for further growth despite its strong performance against rivals.
2026-06-11 18:15:26
Truist Securities has lowered its price target for Insulet Corporation (NASDAQ:PODD) to $219 from $250, while maintaining a Buy rating. The valuation adjustment is based on a 4x EV/Sales multiple on the firm's 2027 estimated revenue, citing looming competition and long-term concerns about GLP-1s, despite the stock appearing undervalued by InvestingPro analysis. This change comes amid recent medical device corrections by Insulet, although Benchmark has reiterated a Buy rating with a $250 price target.
2026-06-11 17:17:00
Insulet Corp. (PODD) shares dropped 1.01% on Thursday, closing at $149.19, despite an overall positive day for the stock market. Both the S&P 500 Index and the Dow Jones Industrial Average saw significant gains. This marks the second consecutive day of losses for the company's stock.
2026-06-11 15:10:30
Insulet is developing a "fully closed loop" automated insulin delivery system for Type 2 diabetes that distinguishes itself from competitors by requiring no carb-counting, insulin bolusing, or initial programming by physicians. The system, which automated dose titration and has no bolus button, showed promising results in its Evolution 3 study, improving participants' time in range and reducing total daily insulin without weight gain. Insulet also shared findings for its Omnipod 6 algorithm, designed for both Type 1 and Type 2 diabetes, which offers a lower glucose target and improved connectivity, with an FDA submission planned for this year and a launch next year.
2026-06-11 13:21:00
Truist Securities analyst Richard Newitter has lowered the price target for Insulet Corporation (PODD) from $250.00 to $219.00. The analyst maintained their rating on the stock. Full access to the analyst's complete report and other premium news requires a StreetInsider.com Premium subscription.
2026-06-11 07:08:26
Erste Asset Management GmbH has acquired 21,889 shares of Insulet Corporation (NASDAQ:PODD), valued at approximately $6.27 million, marking a new position for the firm. Despite recent downward adjustments in price targets by several analysts, Insulet maintains a "Moderate Buy" consensus rating with an average target price of $250. The company recently surpassed Q1 earnings expectations with EPS of $1.42 and a 33.9% year-over-year revenue increase to $761.7 million.
